{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Luan F"],"funding":["NIAID NIH HHS"],"pagination":["e202503335"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12559151"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["9(1)"],"pubmed_abstract":["T cells are one of the most powerful weapons to fight cancer; however, T-cell exhaustion and dysfunction restrict their long-lasting function in antitumor immunity. B-cell lymphoma 6 (BCL6) has many functions in CD8 T cells; however, it is unclear how it regulates the effector function and exhaustion of CD8 cells. Overall, a low level of BCL6 mRNA in human cancer samples is associated with better outcomes, but high expression of BCL6 is specifically observed in cytotoxic CD8 T cells. We found that BCL6 deficiency in activated CD8 T cells enhanced tumor repression in multiple mouse models. More IL-2-expressing CD8 T cells and reduced proportions of exhausted or dysfunctional CD8 T cells were detected within tumors when <i>Bcl6</i> was knocked out upon T-cell activation. Glycolysis was promo"],"journal":["Life science alliance"],"pubmed_title":["Loss of &lt;i&gt;Bcl6&lt;/i&gt; promotes antitumor immunity by activating glycolysis to rescue CD8 T-cell function."],"pmcid":["PMC12559151"],"funding_grant_id":["R01 AI137252"],"pubmed_authors":["Blane TR","Luan F","Li Y","Tran JT","Huang Z","Nemazee D","Ning J","Bhargava R","Xiao C"],"additional_accession":[]},"is_claimable":false,"name":"Loss of &lt;i&gt;Bcl6&lt;/i&gt; promotes antitumor immunity by activating glycolysis to rescue CD8 T-cell function.","description":"T cells are one of the most powerful weapons to fight cancer; however, T-cell exhaustion and dysfunction restrict their long-lasting function in antitumor immunity. B-cell lymphoma 6 (BCL6) has many functions in CD8 T cells; however, it is unclear how it regulates the effector function and exhaustion of CD8 cells. Overall, a low level of BCL6 mRNA in human cancer samples is associated with better outcomes, but high expression of BCL6 is specifically observed in cytotoxic CD8 T cells. We found that BCL6 deficiency in activated CD8 T cells enhanced tumor repression in multiple mouse models. More IL-2-expressing CD8 T cells and reduced proportions of exhausted or dysfunctional CD8 T cells were detected within tumors when <i>Bcl6</i> was knocked out upon T-cell activation. Glycolysis was promo","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Jan","modification":"2026-06-05T07:14:20.88Z","creation":"2026-05-14T03:09:10.433Z"},"accession":"S-EPMC12559151","cross_references":{"pubmed":["41145211"],"doi":["10.26508/lsa.202503335"]}}